| Gene name: | IL22 |
| Aging type: | Accelerate |
| Aging characteristic: |
| Tissue type: | Liver |
| Cell name: | HSC |
| Gene ID: | 50616 |
| Category: | protein coding |
| Phenotype: | Liver disease |
| Experimental category: | L |
| PMID: | 22473749 |
| Experiment: | SA-β-gal activity assay//Immunohistochemistry//qRT-PCR//Western blot |
| Description: | Immunohistochemistry staining revealed an increase in the number of SA‐β‐Gal+ cells in livers of Ad‐IL‐22‐treated mice than in the livers of Ad‐GFP‐treated mice, and these cells tended to reside within fibrotic scar tissue.Approximately 60% of HSCs from Ad‐IL‐22‐treated mice were positive for SA‐β‐Gal staining, whereas only 20% of HSCs from Ad‐GFP‐treated mice were positive.IL‐22 treatment increased the number of SA‐β‐Gal+ HSCs, but decreased telomerase activity in HSCs. IL‐22 exposure up‐regulated the expression of several cellular senescence‐associated proteins, including phosphorylated p53 at serine 15 (p‐p53ser15), p53, p21, and SOCS3. |
| Target gene: | STAT3//P53//SOCS3 |
| Official symbol(s): | STAT3//P53//SOCS3 |
| R-AG-Target gene: | Activation//Upregulation//Upregulation |
| Subcategory: | Unclear |
| Target gene experiment: | SA-β-gal activity assay//qRT-PCR//Western blot//Knockdown |
| Target gene description: | STAT3 protein deletion was confirmed by western blotting. IL‐22 treatment up‐regulated SA‐β‐Gal activity and the expression of p‐p53ser15, p53, and p21 in WT HSCs, but not in STAT3?/? HSCs.The expression of Flag‐caSTAT3 was confirmed by western blotting. Infection with Ad‐Flag/caSTAT3 markedly decreased α‐SMA protein expression , but increased SA‐β‐Gal staining in HSCs . Moreover, the introduction of Flag‐caSTAT3 increased the expression of p‐p53ser15, p53, and p21 in HSCs .IL‐22 exposure up‐regulated the expression of SOCS3 mRNA and protein in HSCs.IL‐22 treatment or caSTAT3 overexpression up‐regulated both p53 and SOCS3 proteins.The effects of IL-22 on the signaling pathways in HSCs. IL-22 exposure significantly activated STAT3 in all samples with peak effects observed at 30-60 min. Furthermore, IL-22-dependent STAT3 activation in HSCs was further confirmed by immunostaining for pSTAT3 in the nuclei of HSCs. |
| Regulatory pathway: | -- |
| R-AG-Pathway: | -- |
| Pathway experiment: | -- |
| Pathway description: | -- |
Annotation:
Loading,please wait...